Immunomagnetic Assay Using Upconversion Nanoparticles for the
Detection of Prostate-Specific Antigen

a 2022

Immunomagnetic Assay Using Upconversion Nanoparticles for the Detection of Prostate-Specific Antigen

SKLENÁROVÁ, Dorota, Ekaterina MAKHNEVA, Julian BRANDMEIER, Hans-Heiner GORRIS, Zdeněk FARKA et. al.

Základní údaje

Originální název

Immunomagnetic Assay Using Upconversion Nanoparticles for the Detection of Prostate-Specific Antigen

Autoři

SKLENÁROVÁ, Dorota, Ekaterina MAKHNEVA, Julian BRANDMEIER, Hans-Heiner GORRIS a Zdeněk FARKA

Vydání

NANOCON 2022, 2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

10406 Analytical chemistry

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Organizační jednotka

Přírodovědecká fakulta

ISBN

978-80-88365-07-5

Klíčová slova anglicky

immunoassay; magnetic microparticles; immunoseparation; prostate-specific antigen; photon-upconversion nanoparticles

Příznaky

Mezinárodní význam

Změněno: 10. 11. 2022 15:34, Mgr. Dorota Sklenárová

Anotace

V originále

Prostate-specific antigen (PSA) is one of the most important biomarkers of prostate cancer, the leading cause of death in the male population caused by oncologic diseases. Sensitive biomarker detection is essential for early-stage disease diagnosis, enabling more effective treatment. Immunochemical methods, such as enzyme-linked immunosorbent assay (ELISA), are considered the gold standard for PSA detection. However, there are several limitations that render ELISA insufficient regarding the sensitivity required for early-stage diagnosis. Photon-upconversion nanoparticles (UCNPs) are nanocrystals that exhibit anti-Stokes luminescence, thus avoiding optical background interference. When conjugated with biorecognition molecules (antibodies or streptavidin), UCNPs can be used as a sensitive label in various immunoassay formats, including microtiter plate-based upconversion-linked immunosorbent assay (ULISA). However, as many biomarkers are present in extremely low levels, even ULISA may still not be sensitive enough, making it necessary to search for new, even more sensitive approaches. Magnetic microparticles represent a promising alternative for microtiter plates used in immunoassays, mainly for their superparamagnetic properties that allow for analyte preconcentration and thus higher assay sensitivity. We have developed a sandwich immunoassay for PSA based on magnetic microparticles and UCNP-based labels. The assay reached an LOD of 93 pg/mL, comparable to an ELISA using identical immunoreagents. Consequently, magnetic preconcentration was utilized, resulting in an LOD of 0,46 pg/mL, which represents a 31-fold improvement compared to the ELISA. The achieved results demonstrate the potential of using magnetic microparticles combined with UCNPs for the sensitive detection of cancer biomarkers.

Návaznosti

GA21-03156S, projekt VaV

Název: Foton-upkonverzní značky pro mikrofluidní jednomolekulové imunostanovení proteinových biomarkerů

Investor: Grantová agentura ČR, Foton-upkonverzní značky pro mikrofluidní jednomolekulové imunostanovení proteinových biomarkerů

Citovat

SKLENÁROVÁ, Dorota, Ekaterina MAKHNEVA, Julian BRANDMEIER, Hans-Heiner GORRIS a Zdeněk FARKA. Immunomagnetic Assay Using Upconversion Nanoparticles for the Detection of Prostate-Specific Antigen. In NANOCON 2022. 2022. ISBN 978-80-88365-07-5.

@proceedings{2230763,
   author = {Sklenárová, Dorota and Makhneva, Ekaterina and Brandmeier, Julian and Gorris, HansandHeiner and Farka, Zdeněk},
   booktitle = {NANOCON 2022},
   keywords = {immunoassay; magnetic microparticles; immunoseparation; prostate-specific antigen; photon-upconversion nanoparticles},
   language = {eng},
   isbn = {978-80-88365-07-5},
   title = {Immunomagnetic Assay Using Upconversion Nanoparticles for the Detection of Prostate-Specific Antigen},
   year = {2022}
}

TY  - CONF
ID  - 2230763
AU  - Sklenárová, Dorota - Makhneva, Ekaterina - Brandmeier, Julian - Gorris, Hans-Heiner - Farka, Zdeněk
PY  - 2022
TI  - Immunomagnetic Assay Using Upconversion Nanoparticles for the Detection of Prostate-Specific Antigen
SN  - 9788088365075
KW  - immunoassay
KW  - magnetic microparticles
KW  - immunoseparation
KW  - prostate-specific antigen
KW  - photon-upconversion nanoparticles
N2  - Prostate-specific antigen (PSA) is one of the most important biomarkers of prostate cancer, the leading cause of death in the male population caused by oncologic diseases. Sensitive biomarker detection is essential for early-stage disease diagnosis, enabling more effective treatment. Immunochemical methods, such as enzyme-linked immunosorbent assay (ELISA), are considered the gold standard for PSA detection. However, there are several limitations that render ELISA insufficient regarding the sensitivity required for early-stage diagnosis. Photon-upconversion nanoparticles (UCNPs) are nanocrystals that exhibit anti-Stokes luminescence, thus avoiding optical background interference. When conjugated with biorecognition molecules (antibodies or streptavidin), UCNPs can be used as a sensitive label in various immunoassay formats, including microtiter plate-based upconversion-linked immunosorbent assay (ULISA). However, as many biomarkers are present in extremely low levels, even ULISA may still not be sensitive enough, making it necessary to search for new, even more sensitive approaches. Magnetic microparticles represent a promising alternative for microtiter plates used in immunoassays, mainly for their superparamagnetic properties that allow for analyte preconcentration and thus higher assay sensitivity. We have developed a sandwich immunoassay for PSA based on magnetic microparticles and UCNP-based labels. The assay reached an LOD of 93 pg/mL, comparable to an ELISA using identical immunoreagents. Consequently, magnetic preconcentration was utilized, resulting in an LOD of 0,46 pg/mL, which represents a 31-fold improvement compared to the ELISA. The achieved results demonstrate the potential of using magnetic microparticles combined with UCNPs for the sensitive detection of cancer biomarkers.
ER  -

Podrobný výpis o publikaci